CHF 32.74
(2.66%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 5.42 Billion USD | -5.17% |
2022 | 4.04 Billion USD | -3.52% |
2021 | 4.19 Billion USD | 6.28% |
2020 | 3.94 Billion USD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q1 | 1.19 Billion USD | 29.21% |
2024 Q2 | 1.19 Billion USD | 0.0% |
2023 Q3 | 1.09 Billion USD | 3.07% |
2023 Q1 | 1.08 Billion USD | 0.73% |
2023 FY | 3.83 Billion USD | -5.17% |
2023 Q2 | 1.06 Billion USD | -2.16% |
2023 Q4 | 920.98 Million USD | -15.89% |
2022 Q1 | 1.02 Billion USD | 0.0% |
2022 FY | 4.04 Billion USD | -3.52% |
2022 Q4 | 1.07 Billion USD | 1.35% |
2022 Q3 | 1.06 Billion USD | 0.29% |
2022 Q2 | 1.06 Billion USD | 3.31% |
2021 FY | 4.19 Billion USD | 6.28% |
2020 FY | 3.94 Billion USD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
Relief Therapeutics Holding AG | -10.85 Million CHF | 50054.432% |
Tecan Group AG | 390.46 Million CHF | -1289.251% |
Santhera Pharmaceuticals Holding AG | 99.54 Million CHF | -5349.401% |
Basilea Pharmaceutica AG | 130.84 Million CHF | -4045.943% |
Bachem Holding AG | 176.96 Million CHF | -2965.359% |
Siegfried Holding AG | 320.4 Million CHF | -1593.014% |
Molecular Partners AG | -40.8 Million CHF | 13393.515% |